XOMA Stock Price, News & Analysis (NASDAQ:XOMA)

$26.16 +0.81 (+3.20 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$26.16
Today's Range$25.07 - $26.39
52-Week Range$4.50 - $37.25
Volume78,038 shs
Average Volume150,507 shs
Market Capitalization$206.45 million
P/E Ratio-8.02
Dividend YieldN/A
Beta2.96

About XOMA (NASDAQ:XOMA)

XOMA logoXOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Debt-to-Equity Ratio3.53%
Current Ratio3.45%
Quick Ratio3.45%

Price-To-Earnings

Trailing P/E Ratio-8.02453987730061
Forward P/E Ratio-327.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.56 million
Price / Sales38.30
Cash FlowN/A
Price / CashN/A
Book Value($7.81) per share
Price / Book-3.35

Profitability

Trailing EPS($3.26)
Net Income$-53,530,000.00
Net Margins-3.51%
Return on Equity-1.14%
Return on Assets0.95%

Miscellaneous

Employees18
Outstanding Shares8,140,000

XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) released its quarterly earnings data on Wednesday, November, 9th. The biotechnology company reported ($2.08) EPS for the quarter, topping the consensus estimate of ($2.40) by $0.32. The biotechnology company had revenue of $0.64 million for the quarter, compared to the consensus estimate of $1.29 million. XOMA had a negative return on equity of 1.14% and a negative net margin of 3.51%. The firm's revenue was down 69.1% compared to the same quarter last year. View XOMA's Earnings History.

When will XOMA make its next earnings announcement?

XOMA is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for XOMA.

Where is XOMA's stock going? Where will XOMA's stock price be in 2018?

2 brokers have issued 12-month price objectives for XOMA's stock. Their forecasts range from $33.00 to $49.00. On average, they expect XOMA's stock price to reach $41.00 in the next twelve months. View Analyst Ratings for XOMA.

Who are some of XOMA's key competitors?

Who owns XOMA stock?

XOMA's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (2.42%), Bogle Investment Management L P DE (1.26%), Two Sigma Investments LP (1.09%), Geode Capital Management LLC (0.75%), Macquarie Group Ltd. (0.65%) and AXA (0.42%). Company insiders that own XOMA stock include James R Neal, John Varian, Patrick J Md Phd Scannon, Paul D Rubin and Thomas M Burns. View Institutional Ownership Trends for XOMA.

Who sold XOMA stock? Who is selling XOMA stock?

XOMA's stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG and EAM Investors LLC. Company insiders that have sold XOMA company stock in the last year include James R Neal, John Varian and Thomas M Burns. View Insider Buying and Selling for XOMA.

Who bought XOMA stock? Who is buying XOMA stock?

XOMA's stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Bogle Investment Management L P DE, Two Sigma Investments LP, AXA, Geode Capital Management LLC, IFP Advisors Inc, Citadel Advisors LLC and Macquarie Group Ltd.. View Insider Buying and Selling for XOMA.

How do I buy XOMA stock?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $26.16.

How big of a company is XOMA?

XOMA has a market capitalization of $206.45 million and generates $5.56 million in revenue each year. The biotechnology company earns $-53,530,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. XOMA employs 18 workers across the globe.

How can I contact XOMA?

XOMA's mailing address is 2910 SEVENTH ST, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]


MarketBeat Community Rating for XOMA (XOMA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  472
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

XOMA (NASDAQ:XOMA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 3.002.672.672.25
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $41.00$41.00$28.50$12.00
Price Target Upside: 25.65% upside25.65% upside6.56% downside64.16% upside

XOMA (NASDAQ:XOMA) Consensus Price Target History

Price Target History for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018HC WainwrightReiterated RatingBuy -> Buy$49.00MediumView Rating Details
12/19/2017WedbushReiterated RatingBuy$33.00LowView Rating Details
2/1/2017CowenReiterated RatingHoldN/AView Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesReiterated RatingNeutralN/AView Rating Details
8/5/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
3/12/2016Piper Jaffray CompaniesReiterated RatingHoldN/AView Rating Details
3/11/2016Royal Bank of CanadaReiterated RatingSector Perform$2.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

XOMA (NASDAQ:XOMA) Earnings History and Estimates Chart

Earnings by Quarter for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ XOMA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/6/2017Q3 2017($0.81)$1.98$17.95 million$36.18 millionViewN/AView Earnings Details
8/8/2017Q2 2017$0.34$0.21$10.56 million$10.89 millionViewN/AView Earnings Details
5/9/2017Q1 2017($1.30)($2.30)$0.96 million$0.26 millionViewN/AView Earnings Details
3/16/2017Q4 2016($2.32)($2.89)$0.50 million$0.50 millionViewN/AView Earnings Details
11/9/2016Q3($2.40)($2.08)$1.29 million$0.64 millionViewN/AView Earnings Details
8/3/2016($0.12)($0.13)$0.84 million$0.40 millionViewN/AView Earnings Details
5/4/2016($0.12)($0.07)$1.17 million$3.96 millionViewN/AView Earnings Details
3/9/2016Q415($0.15)$0.21$4.01 million$48.18 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.18)$3.55 million$2.10 millionViewListenView Earnings Details
8/6/2015Q215($0.18)($0.20)$4.38 million$2.54 millionViewListenView Earnings Details
5/7/2015Q115($0.16)($0.19)$4.31 million$2.65 millionViewListenView Earnings Details
3/11/2015Q414($0.14)($0.12)$10.70 million$4.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)($0.17)$7.00 million$5.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)$5.32 million$5.97 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.23)$7.40 million$3.41 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.55)$7.92 million$8.45 millionViewN/AView Earnings Details
11/7/2013Q313($0.18)($0.21)$7.87 million$6.31 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.21)$9.30 million$7.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($3.40)($3.00)$9.42 million$9.45 millionViewN/AView Earnings Details
3/12/2013Q4 2012($4.80)($3.60)ViewN/AView Earnings Details
11/7/2012Q312($0.21)($0.39)$11.69 million$7.30 millionViewN/AView Earnings Details
8/7/2012Q2 2012($4.40)($4.60)ViewN/AView Earnings Details
5/8/2012Q1 2012($5.20)($5.54)ViewN/AView Earnings Details
3/14/2012Q4 2011($5.00)($6.82)ViewN/AView Earnings Details
11/9/2011Q3 2011($6.40)($4.00)ViewN/AView Earnings Details
8/4/2011Q2 2011($4.80)($5.44)ViewN/AView Earnings Details
5/5/2011Q1 2011($8.80)($4.34)ViewN/AView Earnings Details
3/10/2011Q4 2010($14.60)($16.76)ViewN/AView Earnings Details
11/4/2010Q3 2010($16.80)($13.76)ViewN/AView Earnings Details
8/9/2010Q2 2010($20.99)($18.59)ViewN/AView Earnings Details
5/6/2010Q1 2010($17.99)($27.29)ViewN/AView Earnings Details
3/11/2010Q4 2009($9.00)$4.50ViewN/AView Earnings Details
11/9/2009Q3 2009$2.70ViewN/AView Earnings Details
8/6/2009Q2 2009($26.99)($19.79)ViewN/AView Earnings Details
5/7/2009Q1 2009$3.00$16.49ViewN/AView Earnings Details
11/10/2008Q3 2008($26.99)($46.18)ViewN/AView Earnings Details
8/7/2008Q2 2008($29.99)($46.78)ViewN/AView Earnings Details
5/12/2008Q1 2008($17.99)($32.08)ViewN/AView Earnings Details
3/11/2008Q4 2007($32.98)($20.99)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

XOMA (NASDAQ:XOMA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.02)($0.02)($0.02)
Q2 20181$0.02$0.02$0.02
Q3 20181($0.41)($0.41)($0.41)
Q4 20181$0.28$0.28$0.28
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for XOMA (NASDAQ:XOMA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

XOMA (NASDAQ XOMA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.02%
Institutional Ownership Percentage: 37.62%
Insider Trades by Quarter for XOMA (NASDAQ:XOMA)
Institutional Ownership by Quarter for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ XOMA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017James R. NealCEOSell46,296$28.24$1,307,399.04View SEC Filing  
11/15/2017Thomas M BurnsSVPSell22,222$28.69$637,549.1813,538View SEC Filing  
11/13/2017James R. NealCEOSell11,568$30.83$356,641.44View SEC Filing  
11/13/2017Thomas M BurnsCFOSell6,983$30.99$216,403.1713,538View SEC Filing  
5/16/2017John VarianDirectorSell39,540$6.24$246,729.602,344View SEC Filing  
3/21/2017James R. NealVPSell5,105$5.40$27,567.00View SEC Filing  
2/1/2017James R NealVPSell195$4.52$881.4020,566View SEC Filing  
1/9/2017James R. NealVPSell125$5.15$643.75View SEC Filing  
12/21/2016John VarianDirectorSell13,549$5.75$77,906.7541,884View SEC Filing  
12/21/2016Patrick J Md Phd ScannonVPSell3,230$5.75$18,572.508,217View SEC Filing  
11/1/2016James R. NealVPSell150$5.25$787.50View SEC Filing  
10/7/2016James R. NealVPSell2,500$0.45$1,125.00View SEC Filing  
3/22/2016John VarianCEOSell81,022$0.78$63,197.161,189,695View SEC Filing  
3/22/2016Patrick J Md Phd ScannonVPSell14,785$0.78$11,532.30243,727View SEC Filing  
3/22/2016Paul D RubinCMOSell24,194$0.78$18,871.32350,795View SEC Filing  
2/1/2016Patrick J Md Phd ScannonVPSell8,000$1.01$8,080.0094,227View SEC Filing  
12/28/2015Patrick J Md Phd ScannonVPSell8,000$1.37$10,960.00102,227View SEC Filing  
11/23/2015Patrick J Md Phd ScannonVPSell8,000$1.35$10,800.00110,227View SEC Filing  
10/26/2015Patrick J Md Phd ScannonVPSell8,000$1.04$8,320.00118,227View SEC Filing  
7/22/2015Bros. Advisors Lp BakerInsiderSell11,000,000$1.09$11,990,000.00View SEC Filing  
7/15/2015John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
7/15/2015Paul D RubinCMOSell5,000$4.60$23,000.00View SEC Filing  
7/10/2015Paul D RubinCMOSell33,400$4.55$151,970.00View SEC Filing  
6/15/2015John VarianCEOSell10,000$3.64$36,400.00View SEC Filing  
4/15/2015John VarianCEOSell10,000$3.86$38,600.00View SEC Filing  
3/23/2015Paul D RubinCMOSell32,742$3.94$129,003.48View SEC Filing  
3/16/2015John VarianCEOSell10,000$3.72$37,200.00View SEC Filing  
2/2/2015Patrick J Md Phd ScannonVPSell5,000$3.52$17,600.00View SEC Filing  
1/15/2015John VarianCEOSell10,000$3.46$34,600.00View SEC Filing  
1/6/2015Bros. Advisors Lp BakerDirectorSell2,215,400$3.81$8,440,674.00View SEC Filing  
1/2/2015Patrick J Md Phd ScannonVPSell5,000$3.55$17,750.00View SEC Filing  
12/30/2014Bros. Advisors Lp BakerDirectorSell744,000$3.67$2,730,480.00View SEC Filing  
12/19/2014Bros. Advisors Lp BakerDirectorSell1,605,100$4.26$6,837,726.00View SEC Filing  
12/16/2014Bros. Advisors Lp BakerDirectorSell1,033,800$4.46$4,610,748.00View SEC Filing  
12/15/2014John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
12/15/2014Paul D RubinCMOSell1,600$4.63$7,408.00View SEC Filing  
12/9/2014Bros. Advisors Lp BakerDirectorSell392,353$4.62$1,812,670.86View SEC Filing  
12/4/2014Bros. Advisors Lp BakerDirectorSell2,372,206$4.79$11,362,866.74View SEC Filing  
12/1/2014Patrick J Md Phd ScannonVPSell5,000$5.51$27,550.00View SEC Filing  
11/26/2014James R NealVPSell1,678$5.67$9,514.26View SEC Filing  
11/24/2014James R NealVPSell1,032$5.03$5,190.96View SEC Filing  
11/20/2014Paul D RubinCMOSell5,000$4.55$22,750.00View SEC Filing  
11/13/2014Fred KurlandCFOSell8,773$3.89$34,126.97View SEC Filing  
11/13/2014James R NealVPSell4,387$3.89$17,065.43View SEC Filing  
11/13/2014John VarianCEOSell58,844$3.89$228,903.16View SEC Filing  
11/3/2014Patrick J Md Phd ScannonVPSell5,000$4.33$21,650.00View SEC Filing  
10/28/2014Paul D RubinCMOSell5,000$4.57$22,850.00View SEC Filing  
10/15/2014John VarianCEOSell10,000$3.87$38,700.00View SEC Filing  
10/1/2014Patrick J Md Phd ScannonVPSell5,000$4.09$20,450.00View SEC Filing  
9/15/2014John VarianCEOSell10,000$4.56$45,600.00View SEC Filing  
9/15/2014Paul D RubinCMOSell5,000$4.59$22,950.00View SEC Filing  
9/4/2014Paul D RubinCMOSell10,000$4.56$45,600.00View SEC Filing  
9/2/2014Patrick J Md Phd ScannonVPSell5,000$4.31$21,550.00View SEC Filing  
8/18/2014Paul D RubinCMOSell26,748$4.34$116,086.32View SEC Filing  
8/15/2014Fred KurlandCFOSell10,401$4.31$44,828.31View SEC Filing  
8/15/2014John VarianCEOSell64,823$4.30$278,738.90View SEC Filing  
8/15/2014Patrick J Md Phd ScannonVPSell5,871$4.31$25,304.01View SEC Filing  
8/1/2014Patrick J Md Phd ScannonVPSell5,000$3.83$19,150.00View SEC Filing  
7/15/2014John VarianCEOSell10,000$4.03$40,300.00View SEC Filing  
7/1/2014Patrick J Md Phd ScannonVPSell5,000$4.68$23,400.00View SEC Filing  
6/16/2014John VarianCEOSell10,000$4.54$45,400.00View SEC Filing  
6/16/2014Paul D RubinCMOSell11,580$4.54$52,573.20View SEC Filing  
5/28/2014Paul D RubinCMOSell1,785$4.22$7,532.70View SEC Filing  
5/15/2014John VarianCEOSell10,000$3.55$35,500.00285,613View SEC Filing  
4/15/2014John VarianCEOSell10,000$4.06$40,600.00285,613View SEC Filing  
3/18/2014Fred KurlandCFOSell5,915$6.32$37,382.8062,600View SEC Filing  
3/18/2014John VarianCEOSell21,329$6.32$134,799.28285,613View SEC Filing  
3/18/2014Patrick Md Phd ScannonVPSell3,419$6.32$21,608.0891,546View SEC Filing  
3/18/2014Paul RubinCMOSell17,649$6.31$111,365.1990,719View SEC Filing  
3/18/2014Thomas KleinInsiderSell30,965$6.32$195,698.8093,150View SEC Filing  
3/17/2014John VarianCEOSell10,000$6.03$60,300.00270,035View SEC Filing  
2/18/2014John VarianCEOSell10,000$7.55$75,500.00148,739View SEC Filing  
2/18/2014Paul RubinCMOSell6,000$7.55$45,300.003,228View SEC Filing  
1/21/2014Paul RubinCMOSell6,000$8.27$49,620.003,228View SEC Filing  
1/15/2014John VarianCEOSell10,000$8.28$82,800.00148,739View SEC Filing  
1/9/2014Patrick Md Phd ScannonVPSell20,000$8.00$160,000.0042,017View SEC Filing  
12/18/2013Paul RubinCMOSell6,000$5.67$34,020.003,534View SEC Filing  
12/16/2013John VarianCEOSell10,000$5.44$54,400.00148,739View SEC Filing  
12/2/2013Patrick Md Phd ScannonVPSell20,000$6.00$120,000.0042,017View SEC Filing  
11/27/2013Paul RubinCMOSell4,696$4.54$21,319.843,534View SEC Filing  
11/18/2013Paul RubinCMOSell1,304$4.08$5,320.323,534View SEC Filing  
11/15/2013John VarianCEOSell64,932$3.95$256,481.40148,739View SEC Filing  
10/15/2013John VarianCEOSell10,000$4.60$46,000.00103,006View SEC Filing  
9/18/2013Paul RubinCMOSell6,000$4.53$27,180.008,329View SEC Filing  
9/16/2013John VarianCEOSell10,000$4.59$45,900.00103,006View SEC Filing  
8/19/2013Bros. Advisors Lp BakerDirectorBuy2,757,791$3.62$9,983,203.42View SEC Filing  
8/19/2013Paul RubinCMOSell6,000$3.74$22,440.0014,329View SEC Filing  
8/15/2013John VarianCEOSell61,647$3.87$238,573.89103,006View SEC Filing  
8/14/2013Fred KurlandCFOSell7,498$3.86$28,942.2811,820View SEC Filing  
8/14/2013Patrick Md Phd ScannonVPSell6,002$3.86$23,167.7227,711View SEC Filing  
8/14/2013Paul RubinCMOSell10,520$3.86$40,607.2020,329View SEC Filing  
7/18/2013Paul D RubinCMOSell6,000$4.71$28,260.00View SEC Filing  
7/15/2013John VarianCEOSell10,000$4.81$48,100.00View SEC Filing  
5/29/2013Paul D RubinCMOSell1,797$4.16$7,475.52View SEC Filing  
5/20/2013Paul D RubinCMOSell6,000$0.54$3,240.00View SEC Filing  
11/14/2012Fred KurlandCFOSell9,111$2.56$23,324.16View SEC Filing  
11/14/2012John VarianCEOSell40,587$2.56$103,902.72View SEC Filing  
11/14/2012Patrick J Md Phd ScannonEVPSell8,773$2.56$22,458.88View SEC Filing  
10/29/2012Julian BakerDirectorBuy4,722,666$3.00$14,167,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

XOMA (NASDAQ XOMA) News Headlines

Source:
DateHeadline
XOMA (XOMA) Lowered to Hold at Zacks Investment ResearchXOMA (XOMA) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 21 at 2:11 PM
FDA Grants Agios' (AGIO) Leukemia Candidate Priority ReviewFDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
finance.yahoo.com - February 16 at 4:13 PM
Zacks: Brokerages Anticipate XOMA Co. (XOMA) to Post -$0.52 EPSZacks: Brokerages Anticipate XOMA Co. (XOMA) to Post -$0.52 EPS
www.americanbankingnews.com - February 14 at 9:06 PM
Cambridge biotech Enumeral files for bankruptcy, sells cancer drugs - Boston Business JournalCambridge biotech Enumeral files for bankruptcy, sells cancer drugs - Boston Business Journal
www.bizjournals.com - February 6 at 3:21 PM
Theravances NDA for COPD Candidate Gets FDA AcceptanceTheravance's NDA for COPD Candidate Gets FDA Acceptance
finance.yahoo.com - January 31 at 6:11 AM
XOMA (XOMA) versus Osiris Therapeutics (OSIR) Critical SurveyXOMA (XOMA) versus Osiris Therapeutics (OSIR) Critical Survey
www.americanbankingnews.com - January 30 at 7:12 PM
East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs - San Francisco Business TimesEast Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs - San Francisco Business Times
www.bizjournals.com - January 25 at 3:21 PM
East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugsEast Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs
finance.yahoo.com - January 25 at 3:21 PM
XOMA Co. (XOMA) Receives Average Recommendation of "Buy" from BrokeragesXOMA Co. (XOMA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 23 at 5:36 AM
XOMA (XOMA) Earns "Buy" Rating from HC WainwrightXOMA (XOMA) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - January 21 at 11:38 PM
XOMA Co. (XOMA) Expected to Post Quarterly Sales of $4.12 MillionXOMA Co. (XOMA) Expected to Post Quarterly Sales of $4.12 Million
www.americanbankingnews.com - January 14 at 3:38 PM
It was a banner year for stocks, but not everyone shared in the wealthIt was a banner year for stocks, but not everyone shared in the wealth
www.bizjournals.com - January 11 at 4:32 PM
It was a banner year for stocks, but not everyone shared in the wealth.It was a banner year for stocks, but not everyone shared in the wealth.
finance.yahoo.com - January 8 at 4:32 PM
XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General CounselXOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel
finance.yahoo.com - January 8 at 10:36 AM
It was a banner year for stocks, but not everyone shared in the wealth. Heres how Pittsburghs public companies fared.It was a banner year for stocks, but not everyone shared in the wealth. Here's how Pittsburgh's public companies fared.
www.bizjournals.com - January 7 at 12:31 PM
Anika Therapeutics Receives FDA Nod for Bone Repair TherapyAnika Therapeutics Receives FDA Nod for Bone Repair Therapy
finance.yahoo.com - January 3 at 9:45 AM
XOMA Co. (XOMA) Receives Consensus Rating of "Buy" from BrokeragesXOMA Co. (XOMA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 29 at 7:02 AM
Zacks: Analysts Expect XOMA Co. (XOMA) Will Announce Quarterly Sales of $4.12 MillionZacks: Analysts Expect XOMA Co. (XOMA) Will Announce Quarterly Sales of $4.12 Million
www.americanbankingnews.com - December 28 at 6:32 PM
ETFs with exposure to XOMA Corp. : December 27, 2017ETFs with exposure to XOMA Corp. : December 27, 2017
finance.yahoo.com - December 27 at 1:04 PM
Zacks: Analysts Anticipate XOMA Co. (XOMA) Will Post Earnings of -$0.52 Per ShareZacks: Analysts Anticipate XOMA Co. (XOMA) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - December 26 at 11:28 AM
Head to Head Survey: XOMA (XOMA) versus SIGA Technologies (SIGA)Head to Head Survey: XOMA (XOMA) versus SIGA Technologies (SIGA)
www.americanbankingnews.com - December 24 at 11:28 AM
4 Biotech Stocks That More Than Doubled This Year - Nasdaq4 Biotech Stocks That More Than Doubled This Year - Nasdaq
www.nasdaq.com - December 22 at 6:35 PM
Brokers Set Expectations for XOMA Co.s Q1 2018 Earnings (XOMA)Brokers Set Expectations for XOMA Co.'s Q1 2018 Earnings (XOMA)
www.americanbankingnews.com - December 21 at 11:28 AM
Pfizer's Leukemia Drug Gets FDA Nod in First-Line SettingPfizer's Leukemia Drug Gets FDA Nod in First-Line Setting
finance.yahoo.com - December 20 at 4:24 PM
XOMA (XOMA) Rating Reiterated by WedbushXOMA (XOMA) Rating Reiterated by Wedbush
www.americanbankingnews.com - December 19 at 9:02 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of ... - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of ... - PR Newswire (press release)
www.prnewswire.com - December 12 at 4:41 PM
Form 8-K XOMA Corp For: Dec 06 - StreetInsider.comForm 8-K XOMA Corp For: Dec 06 - StreetInsider.com
www.streetinsider.com - December 12 at 4:41 PM
ETFs with exposure to XOMA Corp. : December 11, 2017ETFs with exposure to XOMA Corp. : December 11, 2017
finance.yahoo.com - December 11 at 4:35 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - December 11 at 11:12 AM
XOMA Corporation (XOMA) Expected to Announce Quarterly Sales of $1.61 MillionXOMA Corporation (XOMA) Expected to Announce Quarterly Sales of $1.61 Million
www.americanbankingnews.com - December 10 at 5:44 AM
 Brokerages Expect XOMA Corporation (XOMA) to Announce -$0.50 EPS Brokerages Expect XOMA Corporation (XOMA) to Announce -$0.50 EPS
www.americanbankingnews.com - December 8 at 7:46 PM
HC Wainwright Analysts Give XOMA (XOMA) a $38.00 Price TargetHC Wainwright Analysts Give XOMA (XOMA) a $38.00 Price Target
www.americanbankingnews.com - December 8 at 6:06 PM
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation ... - GlobeNewswire (press release)AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation ... - GlobeNewswire (press release)
globenewswire.com - December 8 at 10:36 AM
Today’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma CorporationToday’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma Corporation
finance.yahoo.com - December 8 at 10:36 AM
BRIEF-XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.BRIEF-XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.
www.reuters.com - December 7 at 10:55 AM
XOMA (XOMA) Announces Exclusive Agreement Allowing Rezolute to Develop and Commercialize RZ358XOMA (XOMA) Announces Exclusive Agreement Allowing Rezolute to Develop and Commercialize RZ358
www.streetinsider.com - December 7 at 10:55 AM
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
finance.yahoo.com - December 7 at 10:55 AM
Head-To-Head Analysis: XOMA (XOMA) versus Soligenix (SNGX)Head-To-Head Analysis: XOMA (XOMA) versus Soligenix (SNGX)
www.americanbankingnews.com - December 6 at 1:46 AM
XOMA Corporation (XOMA) Given Consensus Rating of "Buy" by BrokeragesXOMA Corporation (XOMA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 4 at 5:08 AM
XOMA (XOMA) Upgraded to C- by TheStreetXOMA (XOMA) Upgraded to C- by TheStreet
www.americanbankingnews.com - December 1 at 10:34 PM
4 Biotech Stocks to Better Your Financial Health This Winter4 Biotech Stocks to Better Your Financial Health This Winter
www.zacks.com - December 1 at 5:47 PM
ETFs with exposure to XOMA Corp. : November 30, 2017ETFs with exposure to XOMA Corp. : November 30, 2017
finance.yahoo.com - November 30 at 4:24 PM
XOMA Corp. :XOMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017XOMA Corp. :XOMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:38 AM
Head to Head Review: XOMA (XOMA) versus VBI Vaccines (VBIV)Head to Head Review: XOMA (XOMA) versus VBI Vaccines (VBIV)
www.americanbankingnews.com - November 27 at 5:28 AM
XOMA Corporation (XOMA) PT Set at $38.00 by HC WainwrightXOMA Corporation (XOMA) PT Set at $38.00 by HC Wainwright
www.americanbankingnews.com - November 25 at 1:32 PM
Reviewing Jazz Pharmaceuticals PLC (JAZZ) & XOMA Corporation (XOMA)Reviewing Jazz Pharmaceuticals PLC (JAZZ) & XOMA Corporation (XOMA)
www.americanbankingnews.com - November 25 at 1:24 AM
 Brokerages Expect XOMA Corporation (XOMA) Will Announce Quarterly Sales of $1.61 Million Brokerages Expect XOMA Corporation (XOMA) Will Announce Quarterly Sales of $1.61 Million
www.americanbankingnews.com - November 22 at 2:24 AM
 Analysts Anticipate XOMA Corporation (XOMA) Will Announce Quarterly Sales of $1.61 Million Analysts Anticipate XOMA Corporation (XOMA) Will Announce Quarterly Sales of $1.61 Million
www.americanbankingnews.com - November 19 at 10:36 AM
XOMA Corporation (XOMA) Expected to Post Earnings of -$0.50 Per ShareXOMA Corporation (XOMA) Expected to Post Earnings of -$0.50 Per Share
www.americanbankingnews.com - November 17 at 2:04 PM
XOMA Corporation (XOMA) CFO Thomas M. Burns Sells 6,983 SharesXOMA Corporation (XOMA) CFO Thomas M. Burns Sells 6,983 Shares
www.americanbankingnews.com - November 15 at 10:29 PM

SEC Filings

XOMA (NASDAQ:XOMA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

XOMA (NASDAQ:XOMA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

XOMA (NASDAQ XOMA) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.